Dr Rob Adam

Academic Title-Senior Lecturer

UQ Centre for Clinical Research
Faculty of Medicine

Overview

Dr. Robert James Adam MA(Cantab) MBBS (London) MRCP(UK)(Neurology) PhD(UCL) FRACP

Behavioural neurologist with interests in cognition and movement disorders. I am the clinical lead for deep brain stimulation at The Royal Brisbane & Women's Hospital, Senior Lecturer at UQCCR and Research Officer at QIMR.

Clinically, I offer both movement disorders and advanced Parkinson's clinics in addition to statewide Huntington's Disease, Friedreich's Ataxia and Deep Brain Stimulation services https://metronorth.health.qld.gov.au/news/deep-brain-stimulation-parkinsons. I operate a young onset dementia clinic at GARU. I am principal investigator in 2 Phase 1b/2a clinical trials of novel antisense oligonucleotides for Huntington's Disease, PRECISION-HD1 & 2 and their open label extensions. I am part of a nationwide and statewide effort to investigate drug repurposing - particularly in Parkinson's Disease. I collaborate widely in investigator led research with both clinical scientists, basic scientists and allied health practioners both at UQ and beyond. I am a research officer in PISA (Prospective Imaging Study of Aging) https://www.qimrberghofer.edu.au/pisa/ and the clinical lead for ADNet in QLD. ADNet is an NHMRC funded project to screen and register patients with cognitive imapirment.

I was trained in the US (NYU Medical Centre), UK (National Hospital for Neurology & Neurosurgery in Queen Square, UCLH, Cambridge University Hospitals) and Australia (Royal North Shore and Westmead Hospitals, Sydney). My PhD (UCL 2014) Thesis, "Dopamine and Oculomotor Decisions In Health & Disease", investigated the use of eye movement recordings during behavioral tasks to monitor decision making in patients with focal lesions, Parkinson's disease, impulse control disorders and healthy volunteers both under the influence and without the effects of dopaminergic modulators. I teach both medical undergraduates and graduates and have written chapters in medical textbooks.

Research Interests

  • Cognitive Neurology
  • Movement Disorders
  • Parkinson's Disease
  • Tremor
  • Dementia
  • Alzheimer's Disease
  • Huntington's Disease

Research Impacts

Research on biomarkers (PISA study & ADNet) may allow the early identification of "at risk" patients prior to the onset of neurodegenerative disease, thus provding a valuable "window" for intervention.

At the other end of the research spectrum, drug repurposing may discover new benefits of treatments (traditionally used in other disease entitities) for conditions that currently lack disease modifying therapies.

By engaging with community groups (e.g. HD QLD) and industry, we enable our patients to become involved in studies ranging from basic science and fundamental studies of brain function to pharmaceurtical trials of novel investigational agents.

Qualifications

  • Doctor of Philosophy, University College London
  • FRACP, Royal Australasian College of Physicians

Publications

  • Barker, Megan S., Nelson, Nicole L., O'Sullivan, John D., Adam, Robert and Robinson, Gail A. (2018). Energization and spoken language production: evidence from progressive supranuclear palsy. Neuropsychologia, 119349-362. doi:10.1016/j.neuropsychologia.2018.09.004

  • Heyes, Stephanie Burnett, Adam, Robert J., Urner, Maren, van der Leer, Leslie, Bahrami, Bahador, Bays, Paul M. and Husain, Masud (2017). Impulsivity and rapid decision-making for reward. Frontiers in Psychology, 3 (MAY) Article 153, doi:10.3389/fpsyg.2012.00153

  • Yin, Y.W.K., Chang, F.C.F., Mahant, N., Fung, V.S.C., Tsui, D., Aldaajani, Z., Adam, R. and Hely, M. (2016). 2. Antecollis associated with Parkinson’s disease improved following apomorphine therapy. Proceedings of the 16th Biennial Clinical Neurophysiology Workshop of the Australian and New Zealand Association of Neurologists, Gold Coast, QLD, Australia, 27–30 September, 2015. Elsevier BV. doi: 10.1016/j.clinph.2015.11.022

View all Publications

Grants

View all Grants

Supervision

  • Master Philosophy

View all Supervision

Publications

Journal Article

Conference Publication

  • Yin, Y.W.K., Chang, F.C.F., Mahant, N., Fung, V.S.C., Tsui, D., Aldaajani, Z., Adam, R. and Hely, M. (2016). 2. Antecollis associated with Parkinson’s disease improved following apomorphine therapy. Proceedings of the 16th Biennial Clinical Neurophysiology Workshop of the Australian and New Zealand Association of Neurologists, Gold Coast, QLD, Australia, 27–30 September, 2015. Elsevier BV. doi: 10.1016/j.clinph.2015.11.022

  • Chang, F. C. F., Mahant, N., Fung, V. S. C., Tsui, D. S. Y., Aldaajani, Z., Adam, R. and Hely, M. A. (2015). Antecollis associated with Parkinson's disease improved following apomorphine therapy. 19th International Congress of Parkinson's Disease and Movement Disorders, San Diego, CA, United States, 14-18 June 2015. Hoboken, NJ, United States :John Wiley & Sons.

  • Fiddes, Barnaby, Adam, Robert, Donaghy, Alastair, Whyte, Adam and Allen, Chris (2013). The changing face of urgent neurology outpatient referrals. Annual Meeting of the Association-of-British-Neurologists, Glasgow, Scotland, 21-24 May 2013. London, United Kingdom :B M J Group. doi: 10.1136/jnnp-2013-306573.54

  • Adam, R. J., Bays, P. M., Singh-Curry, V., Bain, P. G. and Husain, M. (2009). Oculomotor Impulsivity in Parkinson'S Disease. ABN Joint Annual Meeting/Spanish-Society-of-Neurology, Liverpool England, Jun 22-26, 2009. B M J PUBLISHING GROUP. doi: 10.1136/jnnp.2009.191759r

  • Adam, R., Bays, P. M., Singh-Curry, V., Bain, P. and Husain, M. (2009). A novel task to probe impulsivity in Parkinson's disease. 13th International Congress of Parkinsons Disease and Movement Disorders, Paris, France, 7-11 June 2009. Hoboken, NJ, United States :John Wiley & Sons.

Grants (Administered at UQ)

PhD and MPhil Supervision

Current Supervision

  • Master Philosophy — Associate Advisor